Cognitive biomarkers of psychosis

S. Kristian Hill,Richard S. E. Keefe,John A. Sweeney

DOI: https://doi.org/10.1093/med/9780190653279.003.0023

2020-01-01

Abstract:Historically, the cognitive dysfunction associated with psychotic disorders was thought to result from neuroleptic exposure and/or a late-stage disease processes brought on by the progressive “dementia praecox” effects. More recently, cognitive dysfunction has come into focus as a core feature of psychotic disorders based on the strong link between cognition and functional status, neurodevelopmental patterns of disrupted cognitive development, shared cognitive dysfunction across psychotic disorders, and familial patterns. Focusing on cognitive biomarkers could facilitate identification of intermediate cognitive phenotypes and corresponding treatment targets. Furthermore, cognitive abilities are stable longitudinally and can be assessed with more reliability and objectivity than clinical symptomatology. Thus, a greater emphasis on the emergence of cognitive abnormalities using reliable and objective cognitive biomarkers may allow for tracking of early disease processes. In this manner, cognitive biomarkers could facilitate intervening at an earlier stage of disease and neurodevelopment, when treatments are more likely to be effective.